Results 181 to 190 of about 37,488 (288)

A Multimarker Model for Prostate Cancer Risk Assessment: Improving Diagnostic Accuracy Beyond PSA

The Prostate, EarlyView.
ABSTRACT Objective This study aimed to evaluate the association between biochemical markers and prostate cancer (PCa) risk by analyzing patients with benign prostatic hyperplasia (BPH) and PCa. Additionally, the study sought to assess the diagnostic accuracy of a multimarker model compared to prostate‐specific antigen (PSA) alone.
Penglu Yang, Bin Yang
wiley   +1 more source

Correlation of sdLDL-C and Apob with the degree of cerebral artery stenosis in posterior circulation stroke. [PDF]

Sci Rep
Sun Z, Liu J, Wang A, Si Z.
europepmc   +1 more source

Causal Relationship Between Blood Metabolites and Osteoporosis: A Two-Sample Mendelian Randomization and Genetic Correlation Analysis. [PDF]

Bioengineering (Basel)
Liu X, Yang G, Li Y, Xiao W, Lu B, Wang Y.   +5 more
europepmc   +1 more source

Population Pharmacokinetics and Exposure‐Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Evinacumab, an angiopoietin‐like 3 (ANGPTL3) inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C), independent of low‐density lipoprotein receptor, in patients with homozygous familial hypercholesterolemia (HoFH). A population pharmacokinetic (PK)/pharmacodynamic (PD) model was previously developed to characterize ...
Sébastien Bihorel, Robert Dingman, Jeanne Mendell, Yuhuan Wang, Poulabi Banerjee, Robert Pordy, John D. Davis, A. Thomas DiCioccio, Lutz Harnisch   +8 more
wiley   +1 more source

Apolipoprotein B-3500-Mutation [PDF]

, 2018
D. Peetz, K. J. Lackner
openaire   +2 more sources

Comparison of Model‐Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Evinacumab, an angiopoietin‐like 3 inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). Herein, we report pharmacokinetic and efficacy analyses of evinacumab in < 5‐year‐old patients with HoFH.
Sébastien Bihorel, Robert Dingman, Jeanne Mendell, Katy C. Norman, Richard T. George, Xue‐Qiao Zhao, Robert Pordy, Daniel Garcia, Wendy S. Putnam, Geetha Raghuveer, Brian W. McCrindle, Elena Fornari, Ivo Baric, Shubha Srinivasan, Melissa Diamond, Eliot A. Brinton, John D. Davis, A. Thomas DiCioccio, Lutz Harnisch   +18 more
wiley   +1 more source

Effects of a Multimodal Lifestyle Intervention on Cardiometabolic Markers in People with Progressive Multiple Sclerosis: A Secondary Analysis of a Pilot Study. [PDF]

Nutrients
Martinez AS, Bastian AJ, Shemirani F, Titcomb TJ, Bisht B, Darling WG, Ramanathan M, Shittu M, Gill CM, Snetselaar LG, Wahls TL.   +10 more
europepmc   +1 more source

Use of Model‐Based Meta‐Analysis to Inform the Design of Early Clinical Trials of Anti‐Amyloid Beta Therapies in Alzheimer's Disease

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT To inform an efficient development of new investigational anti‐amyloid beta (anti‐Aβ) monoclonal antibodies (mAbs), a modeling‐and‐simulation‐based strategy was proposed. A general modeling framework that links drug exposures to the time course of amyloid plaque removal and amyloid‐related imaging abnormalities characterized by edema and ...
Sagar S. Bachhav, Ana Victoria Ponce‐Bobadilla, Diana Clausznitzer, Sven Stodtmann, Hao Xiong   +4 more
wiley   +1 more source

Apolipoprotein and sphingolipid measurements: Can be used in the clinical practice of atrial fibrillation diagnosing and evaluating the cryoablation effectiveness? [PDF]

PLoS One
Bielawiec P, Harasim-Symbor E, Gołaszewska K, Chabowski A, Hodun K, Sztolsztener K.   +5 more
europepmc   +1 more source

Apolipoprotein-B gene

Biomedicine & Pharmacotherapy, 1990
openaire   +2 more sources